FDA Clearance Tracker · K242967
Loss of Pulse Detection
Last checked: Nov 20, 2026Latest source record: Feb 25, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Feb 25, 2025
Substantially Equivalent
Time to decision
152 days
Received Sep 26, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K242967
- Device name
- Loss of Pulse Detection
- Applicant
- Fitbit
- Applicant location
- San Francisco, CA
- Received
- Sep 26, 2024
- Decided
- Feb 25, 2025
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Loss Of Pulse Notification Software (SDY)
- Device class
- Class II
- Regulation
- 21 CFR 870.2790
- Specialty
- Cardiology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code SDY (Loss Of Pulse Notification Software).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K242967
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Fitbit
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K243778 · Decided Feb 13, 2025 · 66 days after receipt
Device type: Body Temperature Sensing Software (QZA) · Hospital Medicine & Nursing
- Body Temperature Software (BTS)New device typeDe Novo
DEN230050 · Decided Dec 15, 2023 · 151 days after receipt
Device type: Body Temperature Sensing Software (QZA) · Hospital Medicine & Nursing
K212372 · Decided Apr 8, 2022 · 252 days after receipt
Device type: Photoplethysmograph Analysis Software For Over-The-Counter Use (QDB) · Cardiology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.